In cluster 2, keywords such as bevacizumab, chemoresistance, chemosensitivity, combination, drug resistance, MGMT promoter methylation, radiation therapy, radiosensitivity, radiotherapy, resistance, temozolomide, and trial indicate that the text in this section focuses on issues related to sensitivity, resistance mechanisms, and combination therapy in glioma regarding radiotherapy and chemotherapy and may involve clinical trials. The gene discussed is MGMT; the disease is central nervous system cancer.